Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 12, 2007. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the GlaxoSmithKline Executive Supplemental Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications.
Material Changes
Changes in share interests were reported for three individuals due to the re-investment of dividends paid on October 11, 2007, at a price of $52.26 per share under the Annual Investment Plan feature:
- Dr. JP Garnier: Increase of 386.91 shares
- Dr. D Pulman: Increase of 20.85 shares
- Mr. D Stout: Increase of 317.44 shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a compliance notification regarding insider trading rules (Disclosure and Transparency Rules 3.1.4R(1)(a) and 3.1.4R(1)(b)).
Investor Verification Points
- Verify the dividend re-investment price of $52.26 per share against market data for October 11, 2007.
- Confirm the specific share class (Ordinary share ADRs) involved in the transactions.
- Review the full Annual Investment Plan rules to understand the automatic re-investment mechanism.